Application of Interpretable Machine Learning Models Based on Ultrasonic Radiomics for Predicting the Risk of Fibrosis Progression in Diabetic Patients with Nonalcoholic Fatty Liver Disease

References

• Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547–1554. doi:10.1002/hep.27368
   PubMed Web of Science ®Google Scholar
• Taylor RS, Taylor RJ, Bayliss S, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology. 2020;158(6):1611–1625.e1612. doi:10.1053/j.gastro.2020.01.043
   PubMed Web of Science ®Google Scholar
• Hagström H, Nasr P, Ekstedt M, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67(6):1265–1273. doi:10.1016/j.jhep.2017.07.027
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793–801. doi:10.1016/j.jhep.2019.06.021
   PubMed Web of Science ®Google Scholar
• Puchakayala BK, Verma S, Kanwar P, Hart J, Sanivarapu RR, Mohanty SR. Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease. World J Hepatol. 2015;7(25):2610–2618. doi:10.4254/wjh.v7.i25.2610
   PubMedGoogle Scholar
• Bian H, Zhu X, Xia M, et al. Impact of type 2 diabetes on nonalcoholic steatohepatitis and advanced fibrosis in patients with nonalcoholic fatty liver disease. Endocr Pract. 2020;26(4):444–453. doi:10.4158/EP-2019-0342
   PubMed Web of Science ®Google Scholar
• Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments. Nat Rev Gastroenterol Hepatol. 2021;18(9):599–612. doi:10.1038/s41575-021-00448-y
   PubMed Web of Science ®Google Scholar
• Wong VW, Wong GL, Choi PC, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut. 2010;59(7):969–974. doi:10.1136/gut.2009.205088
   PubMed Web of Science ®Google Scholar
• Bedossa P, Patel K. Biopsy and noninvasive methods to assess progression of nonalcoholic fatty liver disease. Gastroenterology. 2016;150(8):1811–1822.e1814. doi:10.1053/j.gastro.2016.03.008
   PubMed Web of Science ®Google Scholar
• Campos-Murguía A, Ruiz-Margáin A, González-Regueiro JA, Macías-Rodríguez RU. Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol. 2020;26(39):5919–5943. doi:10.3748/wjg.v26.i39.5919
   PubMed Web of Science ®Google Scholar
• Kaswala DH, Lai M, Afdhal NH. Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016. Dig Dis Sci. 2016;61(5):1356–1364. doi:10.1007/s10620-016-4079-4
   PubMed Web of Science ®Google Scholar
• Barr RG, Wilson SR, Rubens D, Garcia-Tsao G, Ferraioli G. Update to the society of radiologists in ultrasound liver elastography consensus statement. Radiology. 2020;296(2):263–274. doi:10.1148/radiol.2020192437
   PubMed Web of Science ®Google Scholar
• Eddowes PJ, Sasso M, Allison M, et al. Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(6):1717–1730. doi:10.1053/j.gastro.2019.01.042.
   PubMed Web of Science ®Google Scholar
• Siddiqui MS, Vuppalanchi R, Van Natta ML, et al. Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2019;17(1):156–163.e152. doi:10.1016/j.cgh.2018.04.043
   PubMed Web of Science ®Google Scholar
• Zhou Y-J, Ye F-Z, Li -Y-Y, et al. Individualized risk prediction of significant fibrosis in non-alcoholic fatty liver disease using a novel nomogram. United European Gastroenterol J. 2019;7(8):1124–1134. doi:10.1177/2050640619868352
   PubMed Web of Science ®Google Scholar
• Vilar-Gomez E, Yasells-Garcia A, Martinez-Perez Y, et al. Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention. Hepatology. 2016;63(6):1875–1887. doi:10.1002/hep.28484
   PubMed Web of Science ®Google Scholar
• Lambin P, Rios-Velazquez E, Leijenaar R, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012;48(4):441–446. doi:10.1016/j.ejca.2011.11.036
   PubMed Web of Science ®Google Scholar
• D’Souza JC, Sultan LR, Hunt SJ, et al. B-mode ultrasound for the assessment of hepatic fibrosis: a quantitative multiparametric analysis for a radiomics approach. Sci Rep. 2019;9(1):8708. doi:10.1038/s41598-019-45043-z
   PubMedGoogle Scholar
• Sim KC, Kim MJ, Cho Y, et al. Diagnostic feasibility of magnetic resonance elastography radiomics analysis for the assessment of hepatic fibrosis in patients with nonalcoholic fatty liver disease. J Comput Assist Tomogr. 2022;46(4):505–513. doi:10.1097/rct.0000000000001308
   PubMed Web of Science ®Google Scholar
• Jiang T, Gradus JL, Rosellini AJ. Supervised machine learning: a brief primer. Behav Ther. 2020;51(5):675–687. doi:10.1016/j.beth.2020.05.002
   PubMed Web of Science ®Google Scholar
• Wong GL-H, Yuen P-C, Ma AJ, Chan AW-H, Leung HH-W, Wong VW-S. Artificial intelligence in prediction of non-alcoholic fatty liver disease and fibrosis. J Gastroenterol Hepatol. 2021;36(3):543–550. doi:10.1111/jgh.15385.
   PubMed Web of Science ®Google Scholar
• Association AD. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2020. Diabetes Care. 2019;43(1):S14–S31. doi: 10.2337/dc20-S002
   Google Scholar
• European Association for the Study of the Liver EAftSoD, European Association for the Study of Obesity. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Obesity Facts. 2016;9(2):65–90. doi: 10.1159/000443344
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American association for the study of liver diseases, American college of gastroenterology, and the American gastroenterological association. Am J Gastroenterol. 2012;107(6):811–826. doi:10.1038/ajg.2012.128
   PubMed Web of Science ®Google Scholar
• Tian J, Dong D, Liu Z, et al.. Radiomics in Medical Imaging—Detection, Extraction and Segmentation. In: Suzuki K, Chen Y, editors. Artificial Intelligence in Decision Support Systems for Diagnosis in Medical Imaging. Cham: Springer International Publishing; 2018:267–333.
   Google Scholar
• Nohara Y, Matsumoto K, Soejima H, Nakashima N. Explanation of Machine Learning Models Using Improved Shapley Additive Explanation. Proceedings of the 10th ACM International Conference on Bioinformatics, Computational Biology and Health Informatics. Niagara Falls, NY, USA: Association for Computing Machinery; 2019:546.
   Google Scholar
• Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643–654. doi:10.1016/j.cgh.2014.04.014..
   PubMed Web of Science ®Google Scholar
• Lee HW, Wong GLH, Kwok R, et al. Serial transient elastography examinations to monitor patients with type 2 diabetes: a prospective cohort study. Hepatology. 2020;72(4):1230–1241. doi:10.1002/hep.31142
   PubMed Web of Science ®Google Scholar
• Xia J, Jin G, Hua Q, Cui S, Li J. Nomogram for quantitatively estimating the risk of fibrosis progression in type 2 diabetic patients with nonalcoholic fatty liver disease: a pilot study. Front Endocrinol. 2022;13:917304. doi:10.3389/fendo.2022.917304
   PubMed Web of Science ®Google Scholar
• Uddin S, Khan A, Hossain ME, Moni MA. Comparing different supervised machine learning algorithms for disease prediction. BMC Med Inform Decis Mak. 2019;19(1):281. doi:10.1186/s12911-019-1004-8
   PubMed Web of Science ®Google Scholar
• Nohara Y, Matsumoto K, Soejima H, Nakashima N. Explanation of machine learning models using shapley additive explanation and application for real data in hospital. Comput Methods Programs Biomed. 2022;214:106584. doi:10.1016/j.cmpb.2021.106584
   PubMed Web of Science ®Google Scholar
• Xue B, Li D, Lu C, et al. Use of machine learning to develop and evaluate models using preoperative and intraoperative data to identify risks of postoperative complications. JAMA Netw Open. 2021;4(3):e212240. doi:10.1001/jamanetworkopen.2021.2240
   PubMed Web of Science ®Google Scholar